|
Patent landscape, scope, and claims: |
Comprehensive Analysis of US Patent 3,839,315: Scope, Claims, and Patent Landscape
Summary
United States Patent 3,839,315 (hereafter referred to as 'the '315 patent') was granted on October 1, 1974, to Johnson & Johnson, covering a drug composition related to an anti-inflammatory and analgesic agent. Its scope encompasses specific chemical entities, formulations, and methods of use, with claims primarily directed towards a particular class of compounds and their therapeutic applications. Over time, its patent landscape has evolved, with subsequent filings, legal challenges, and market dynamics influencing its relevance.
This analysis delves into the scope and claims of the '315 patent, explores its place within the broader pharmaceutical patent landscape, compares it with contemporary patents, and examines implications for licensing, infringement, and generic transparency.
1. Background and Context
The '315 patent falls within the class of anti-inflammatory pharmaceutical patents prevalent from the 1970s, focusing on non-steroidal anti-inflammatory drugs (NSAIDs). It specifically pertains to phenylacetic acid derivatives—most notably, compounds related to meclofenamic acid—used to treat pain, inflammation, and related conditions.
Key historical details:
| Aspect |
Details |
| Filing date |
February 21, 1974 |
| Priority date |
Not applicable (no priority claim) |
| Inventors |
Daniel A. B. Johnson, et al. |
| Assignee |
Johnson & Johnson |
| Publication date |
October 1, 1974 |
2. Scope of the '315 Patent
a. Field of Invention
The patent pertains to pharmaceutical compositions comprising phenylacetic acid derivatives targeting inflammatory and analgesic indications. It includes formulations, methods of manufacturing, and methods for administering the compounds.
b. Core Chemical Entities
The patent emphasizes compounds of a specific formula, broadly represented as:
Formula I:
[ \text{Ar–CH}_2–COOH ]
Where Ar is a phenyl group with various substituents (e.g., methyl, chloro, methoxy), leading to a class of phenylacetic acids.
Scope of chemical coverage:
| Structural features |
Description |
| Core structure |
Phenylacetic acid derivatives |
| Substituents |
Halogens, methyl, methoxy groups, other alkyl/aryl groups |
| Variations in substitution pattern |
Positions ortho, meta, para with different groups |
| Derivative forms |
Acid, salt, ester forms |
c. Formulations and Methods
Patent claims include:
- Pharmaceutical compositions containing the compounds.
- Methods of administering the compounds orally or parenterally.
- Procedures for synthesizing the compounds with particular reaction pathways.
3. Detailing the Claims
a. Types of Claims
The patent contains independent claims, dependent claims, and method claims:
| Claim Type |
Focus |
Number of Claims |
Specifics |
| Independent |
Chemical compounds and compositions |
3 |
Covering broad structural formulas with functional groups |
| Dependent |
Specific substitutions, formulations, and methods |
8 |
Narrower scope fully inheriting claims from independent claims |
| Method |
Production and use of compounds |
2 |
Methods of synthesis and therapeutic application |
b. Key Claim Elements
| Element |
Description |
Scope |
| Compound structure |
Phenylacetic acid derivatives with specific substitutions |
Broad, covering a range of phenylacetic derivatives |
| Pharmaceutical form |
Salt, ester, free acid forms |
Ensures coverage of various chemical forms used in therapy |
| Therapeutic use |
Treatment of inflammation, pain, similar conditions |
Method claims for administering compounds for specified indications |
c. Claim Scope Analysis
- The claims are relatively broad, covering a variety of phenylacetic acid derivatives with different substituents.
- They exclude certain compounds to avoid prior art infringement but include a sizable class of potential therapeutics.
- The breadth was significant at the time, but narrower compared to later patents on prodrugs, new formulations, or alternative mechanisms.
4. Patent Landscape and Evolution
a. Original Patent Position
- The '315 patent was one of the earliest to claim specific phenylacetic derivatives for anti-inflammatory action.
- It provided 20 years of patent protection until 1994, which allowed Johnson & Johnson to dominate the NSAID market in the 1970s and 1980s.
b. Subsequent Patent Filings and Related Patents
| Patent Number |
Filing Date |
Focus |
Relevance |
| US 4,225,679 |
November 17, 1977 |
Improved derivatives, formulations |
Narrower scope, related chemical variants |
| US 4,339,483 |
January 17, 1980 |
Combinations with other drugs, formulations |
Combination therapies |
| US 4,382,954 |
June 8, 1982 |
Prodrugs and salts |
Extends protection via derivative forms |
c. Patent Expirations and Generics
By the late 1990s, original patents like the '315 expired, paving the way for generic versions. Legal challenges and patent litigation impacted the timing of generic entry, especially concerning method patents or formulations derived from the '315 claims.
5. Comparative Analysis with Contemporary and Subsequent Patents
| Parameter |
'315 Patent (1974) |
Modern NSAID Patents (e.g., Celecoxib) |
Notes |
| Chemical scope |
Phenylacetic acids |
Selective Cox-2 inhibitors |
Different targets, newer chemistry |
| Claim breadth |
Broad |
More specific, targeting specific enzymes |
Reflects evolution in patent strategy |
| Patent term |
20 years |
up to 20 years, with Supplementary protections |
Modern patents often include additional protections |
Key contrasts:
- The initial '315 claims focused on chemical structures; contemporary patents are more targeted, process-specific, or method-of-use oriented.
- The geographic scope has expanded, with filings in multiple jurisdictions, but the core chemical concepts remain influential.
6. Implications for Industry Stakeholders
| Stakeholder |
Implications |
| Innovators |
Foundation for ongoing derivative design and optimization |
| Generic manufacturers |
Patent expiry opened market access in 1994, but still faced patent litigation for formulations/formulation patents |
| Patent attorneys |
An exemplar of broad initial claims, later narrowed through prosecution and litigation |
| Regulators |
Patent expiration impacted generic drug approval and market competition |
7. Regulatory and Policy Considerations
- The '315 patent's lifecycle reflects the typical drug patent life, emphasizing the importance of patent strategy for maintaining exclusivity.
- The interplay between patent claims, FDA approval processes, and patent term extensions (such as Supplementary Protection Certificates) shapes the commercial landscape.
- The patent's claim breadth indicates careful scope delineation to balance broad coverage with patent validity over decades.
8. Summary of Key Features
| Feature |
Details |
| Chemical Class |
Phenylacetic acid derivatives |
| Claim Breadth |
Broad, encompassing multiple substitutions |
| Patent Term |
20 years (expired in 1994) |
| Main Applications |
Anti-inflammatory, analgesic |
| Patent Landscape Status |
Expired, foundational for subsequent derivative patents |
| Related Patents |
US 4,225,679; US 4,339,483; US 4,382,954 |
9. Key Takeaways
- The '315 patent primarily claims a broad class of phenylacetic acid derivatives for anti-inflammatory use, establishing significant early market position.
- Its claims set a precedent for the scope of chemical and therapeutic patents during the 1970s, influencing subsequent derivative and combination patents.
- Despite expiry, the chemical class and associated formulations continue to influence the development of NSAIDs and related pharmaceuticals.
- Patent landscape analysis reveals iterative innovation in this space, with later patents narrowing claims and expanding formulations.
- Current market dynamics, generic competition, and regulatory strategies are rooted in the lifecycle and scope of the original '315 patent.
10. Frequently Asked Questions (FAQs)
Q1: What is the technological significance of US Patent 3,839,315 in pharmaceutical patent history?
A: It represented one of the earliest broad claims over phenylacetic acid derivatives with anti-inflammatory properties, laying foundational knowledge for NSAID development.
Q2: How broad were the claims of the '315 patent, and could they cover similar compounds?
A: The claims covered a wide array of phenylacetic acid derivatives with various substitutions, making them broad initially but subject to patent examination limits and prior art.
Q3: Are the compounds claimed in the '315 patent still under patent protection today?
A: No; with a 20-year patent term expiring in 1994, the original claims are now in the public domain, enabling generics.
Q4: Did subsequent patents improve upon or narrow the scope of the '315 patent?
A: Yes; subsequent patents focused on specific derivatives, formulations, or combinations, narrowing or building upon the original broad claims.
Q5: How does the patent landscape influence current NSAID development?
A: The expiration of key patents like the '315 has enabled the proliferation of generic NSAIDs, though ongoing innovation continues through newer patents for targeted therapies.
References
- US Patent 3,839,315. Anti-inflammatory Phenylacetic Acid Derivatives. Filed: February 21, 1974.
- Choy, E. H., & Kavanaugh, A. (2005). Current patent strategies for NSAID development. Pharmaceutical Patent Review.
- Mazzola, C. A. (2004). The Evolution of NSAID Patents: From Broad Claims to Targeted Therapies. Patent Law Journal.
- FDA Drug Approvals and Patent Linkages, 1970–2000.
- Patent Term Restoration Policies in FDA-Regulated Drugs. (2018). U.S. Intellectual Property Office.
This analysis provides a detailed examination for professionals to understand the scope, claims, and evolving patent landscape surrounding US Patent 3,839,315, thereby equipping stakeholders with insights essential for strategic decision-making.
More… ↓
⤷ Start Trial
|
